woman 21 years of age or older

the subject is able and willing to comply with study procedures and signed and dated informed consent is obtained.

newly diagnosed with breast cancer (dcis or invasive) identified through core biopsy or fine-needle aspiration (fna) within last 30 days.

will have or have had a bilateral ce-bmri performed within 30 days after the new breast cancer diagnosis.

woman who has already had a lumpectomy for the index lesion.

woman undergoing neoadjuvant chemotherapy treatment, hormone treatment or radiation therapy.

woman who is pregnant or who believe she may be pregnant.

woman who has breast implant.

woman who has a contraindication to the intravenous use of iodinated or gadolinium-chelated contrast agent (e.g., allergy to either agent or severely impaired renal function).